Search Results 91-100 of 13140 for Tyrosine

1. Multidisciplinary Training in Digestive Diseases student roster - Mayo Clinic Research

   Gores, M.D.. Research focus. Tyrosine phosphatase activity alters cholangiocarcinoma. View trainee's publications. Subhankar Chakraborty, M.B.B.S., Ph.D. Mentor.

2. A Study To Evaluate The Effectiveness And Safety Of Benralizumab In Patients With Hypereosinophilic Syndrome (HES) - Mayo Clinic

   Presence of FIP1L1-PDGFRA fusion tyrosine kinase gene translocation or other known imatinib-sensitive mutation. 3. Clinical diagnosis of eosinophilic ...

3. Mayo Clinic researchers identify a potential new approach to treat HER2 positive breast cancer

   “The HER2 receptor tyrosine kinase, which functions as an 'on' or 'off' switch in cellular functions, is a key driver of breast cancer, and is overexpressed ...

4. Gastrointestinal stromal tumor (GIST) - Diagnosis and treatment - Mayo Clinic

   For GISTs, the target of these medicines is an enzyme called tyrosine kinase that helps cancer cells grow. Targeted therapy for GISTs often begins with ...

5. Reimagining osteoporosis: How senolytics are opening a new frontier in bone health - Mayo Clinic

   Through transcriptomic and bioinformatic approaches, researchers identified that a combination of two existing compounds — dasatinib, a tyrosine kinase ...

6. Clinical trials - Oncology (Medical)

   Patients with ALK aberrant tumors (ALK tyrosine kinase mutation or ALK amplification) will be non-randomly assigned to receive crizotinib added to current COG ...

7. Publications - Andrew C. Greenlund, M.D., Ph.D. - Mayo Clinic

   Stat3 recruitment by two distinct ligand-induced, tyrosine-phosphorylated docking sites in the interleukin-10 receptor intracellular domain. J Biol Chem ...

8. A Safety Study Of SYNT001 In Subjects With Chronic, Stable Warm Autoimmune Hemolytic Anemia (WAIHA) - Mayo Clinic

   Stable (<10% change in dose) for 6 weeks prior to screening; Bruton's tyrosine kinase inhibitor dose must be stable (<10% change in dose) for 8 weeks prior ...

9. Publications - Konstantinos Leventakos, M.D., Ph.D. - Mayo Clinic

   ... Tyrosine Kinase Inhibitor Treatment and Overall Survival in ALK Fusion-Positive NSCLC: Real-World Outcomes From the GuardantINFORM database. J Thorac Oncol ...

10. Iobenguane I-131 Or Crizotinib And Standard Therapy In Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma Or Ganglioneuroblastoma - Mayo Clinic

    Patients with ALK aberrant tumors (ALK tyrosine kinase mutation or ALK amplification) will be non-randomly assigned to receive crizotinib added to current COG ...